Nektar Therapeutics
NKTR
#8076
Rank
ยฃ0.14 B
Marketcap
ยฃ0.80
Share price
1.00%
Change (1 day)
113.50%
Change (1 year)

P/E ratio for Nektar Therapeutics (NKTR)

P/E ratio as of November 2024 (TTM): -0.6196

According to Nektar Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.619632. At the end of 2022 the company had a P/E ratio of -1.15.

P/E ratio history for Nektar Therapeutics from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
2022-1.15-75.71%
2021-4.72-30.81%
2020-6.83-20.31%
2019-8.57-202.69%
20188.34-108.8%
2017-94.8749.82%
2016-11.2-60.28%
2015-28.1-22.09%
2014-36.0344.63%
2013-8.1164.11%
2012-4.944.98%
2011-4.71-84.99%
2010-31.3273.27%
2009-8.40-44.12%
2008-15.0-19.38%
2007-18.6112%
2006-8.7915.37%
2005-7.62-48.42%
2004-14.8-8.82%
2003-16.2289.02%
2002-4.167.1%
2001-3.89

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
20.5-3,406.41%๐Ÿ‡บ๐Ÿ‡ธ USA
13.5-2,280.46%๐Ÿ‡บ๐Ÿ‡ธ USA
54.8-8,946.78%๐Ÿ‡บ๐Ÿ‡ธ USA
11.4-1,937.72%๐Ÿ‡บ๐Ÿ‡ธ USA
32.4-5,324.52%๐Ÿ‡ฌ๐Ÿ‡ง UK
6.44-1,139.87%๐Ÿ‡บ๐Ÿ‡ธ USA
21.3-3,538.77%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
11.0-1,881.69%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.